CYTEK BIOSCIENCES, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
CYTEK BIOSCIENCES, INC. (CTKB) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $4.95 million as of 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Notes
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2023-03-01
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $4.95M.
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $0.00.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2022-12-31 | $4.95M 10-K · filed 2023-03-01 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |